Introduction: In this report we firstly describe undifferentiated embryonal sarcoma of the liver (UESL) in a patient with neurofibromatosis type 1 (NF1), fatally complicated by synchronous malignant peripheral nerve sheath tumor (MPNST) with a highly aggressive metastatic course. The case also represents our first experience of chemoperfusion involving the transcatheter arterial chemoembolization (TACE) in a pediatric patient, applied as a treatment for UESL.Case presentation: A 13-year-old girl was diagnosed with NF1 and presented with a liver tumor identified as UESL by histological assessment. The tumor was refractive to the conventional first-line chemotherapy. The patient received hepatic chemoperfusion with TACE, which was efficacious; however, the overall curative outcome was unsatisfactory due to synchronous unresectable retroperitoneal MPNST with mesenteric metastases and ultimate progression of the UESL.Conclusion: This is the first reported case of UESL in a patient with NF1. The results demonstrate the efficacy of hepatic chemoperfusion with TACE in pediatric UESL.
21 December 2020 in Pediatric Hematology/Oncology and Immunopathology
Growing teratoma syndrome (GTS) is reported to have an incidence of 1.9–7.6% among all germ cell tumours (GCT) and is often mistaken for tumor progression. There are no absolute signs or symptoms of GTS but it can be suspected based on the following criteria: the normalization of tumour markers, the enlargement of the mass and the presence in the tumour of mature teratoma cells alone. A delayed tumor resection in GTS can result in higher surgical risks and/or the infeasibility of complete resection. In 72–83% of cases, incomplete resection leads to relapses in the form of mature teratoma growth. A repeat biopsy is recommended in all patients with suspected GTS so that to avoid chemotherapy that would be ineffective in this disease. The article reports two clinical cases of GTS illustrating challenges inherent in the diagnosis of this syndrome. In each case, the parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
2 June 2021 in Bone and soft tissue sarcomas, tumors of the skin
Ewing’s sarcoma is a highly malignant small round cell tumor with a unique rearrangement of the EWSR1 (FUS) gene with partners genes of ETS family. Tumors with Ewing's sarcoma morphological features lacking without specific EWSR1 rear-rangement called undifferentiated small round cell sarcomas of bone and soft tissue. This group includes: sarcomas with СIC gene rearrangement, sarcomas with BCOR gene rearrangement and sarcomas with EWSR1 (FUS) gene rearrangement with non-ETS gene-partner. Clinical, morphological and molecular genetic characteristics of these groups of tumors will be described below
2 November 2025 in Russian Journal of Pediatric Hematology and Oncology
Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.
13 December 2025 in Pediatric Hematology/Oncology and Immunopathology
Introduction. CIC-rearranged sarcoma is the most aggressive tumor of all undifferentiated small round cell sarcomas (USRCSs) of bone and soft tissue, characterized by a high incidence of distant metastases and disease progression during first-line treatment. In this article, we describe clinical, biological and molecular characteristics and tools for quick and precise molecular diagnosis. Aim – to evaluate the molecular features of sarcoma with CIC gene rearrangement and to investigate the clinical and prognostic characteristics in children with CIC-rearranged sarcoma. Materials and methods. We analyzed the clinical and molecular characteristics of 20 patients with the following initial morphological diagnoses: USRCS, undifferentiated spindle cell sarcoma, CIC-rearranged sarcoma. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Results. Fourteen out of 20 patients were diagnosed with CIC-rearranged sarcoma using molecular diagnostic assays. In 12 out of these 14 patients direct molecular markers were identified using RNA sequencing, in 2 patients the diagnosis was confirmed using NanoString’s molecular barcoding technology. Survival analysis was performed for 12 out of 14 patients; the 3-year overall and disease-free survival rates were 34.4 ± 16.0% and 23.8 ± 14.6%, respectively. Conclusion. Patients suspected of CIC-rearranged sarcoma always require comprehensive molecular diagnostic testing to avoid misdiagnosis. CIC-rearranged sarcoma has the most aggressive clinical course of all USRCSs, is characterized by early disease progression and requires a more intensive treatment approach.